









Markets
/
Stocks
/
nasdaq-agen
/

Agenus Inc

AGEN

3.840USD

+0.150+4.07%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

115.22MMarket Cap

LossP/E TTM



Agenus Inc

3.840

+0.150+4.07%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Agenus Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Agenus Inc's Score

Industry at a Glance

Industry Ranking

140 / 407

Overall Ranking

275 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

12.333

Target Price

+230.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Agenus Inc Highlights

StrengthsRisks

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Overvalued

The company’s latest PE is -0.52, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 9.55M shares, decreasing 26.58% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.57M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.54, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 25.69M, representing a year-over-year increase of 9.28%, while its net profit experienced a year-over-year increase of 47.29%.

Score

Industry at a Glance

Previous score

7.54

Change



Financials

3.44

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.19

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.50

Key Metrics

Free cash flow

No Data

Agenus Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 8.46, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.52, which is -71.08% below the recent high of -0.15 and -608.75% above the recent low of -3.70.

Score

Industry at a Glance

Previous score

8.46

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 140/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Agenus Inc is 8.00, with a high of 23.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

12.333

Target Price

+234.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Agenus Inc

AGEN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 3.99, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 4.32 and the support level at 3.35, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.80

Change

0.19

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.039

Sell

RSI(14)

43.932

Neutral

STOCH(KDJ)(9,3,3)

24.539

Neutral

ATR(14)

0.258

Low Volatility

CCI(14)

-86.253

Neutral

Williams %R

78.348

Sell

TRIX(12,20)

-0.313

Sell

StochRSI(14)

75.461

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.840

Buy

MA10

3.919

Sell

MA20

3.999

Sell

MA50

4.180

Sell

MA100

4.722

Sell

MA200

3.867

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 29.96%, representing a quarter-over-quarter decrease of 11.62%. The largest institutional shareholder is The Vanguard, holding a total of 2.57M shares, representing 8.06% of shares outstanding, with 21.46% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

2.53M

-0.66%

Invus Public Equities Advisors, LLC

1.06M

+112.85%

B. Riley Financial, Inc

756.96K

Morgan Stanley & Co. LLC

719.75K

+94.84%

Millennium Management LLC

504.51K

BlackRock Institutional Trust Company, N.A.

489.68K

-69.54%

Marshall Wace LLP

432.48K

AQR Capital Management, LLC

430.88K

-2.40%

BofA Global Research (US)

420.68K

+109.97%

Armen (Garo H.)

338.69K

+2.27%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 3.49, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.53. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.